Vertex Pharmaceuticals Incorporated
VRTX
$435.52
$1.500.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 865.96% | 842.52% | -124.60% | -114.80% | -113.83% |
| Total Depreciation and Amortization | -15.63% | -11.28% | -3.96% | 7.37% | 29.37% |
| Total Amortization of Deferred Charges | 113.56% | 113.56% | 113.56% | 113.56% | -- |
| Total Other Non-Cash Items | 209.86% | 717.51% | 18,338.46% | 16,595.24% | -21.39% |
| Change in Net Operating Assets | -2.27% | -5.45% | -231.49% | -93.75% | -264.52% |
| Cash from Operations | 541.25% | 507.46% | -124.86% | -113.93% | -119.23% |
| Capital Expenditure | -44.68% | -46.84% | -19.10% | -48.55% | -49.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.24% | 59.52% | 55.89% | -18.05% | -87.60% |
| Cash from Investing | 61.42% | 52.55% | 50.95% | -20.00% | -84.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 88.04% | 81.47% | 54.32% | 25.17% | -2.31% |
| Issuance of Common Stock | -14.76% | -18.85% | -16.68% | -14.86% | -9.37% |
| Repurchase of Common Stock | -104.76% | -75.57% | -166.20% | -142.02% | -160.31% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.89% | -17.50% | -16.67% | 244.44% | 322.22% |
| Cash from Financing | -110.51% | -80.68% | -190.85% | -165.90% | -204.18% |
| Foreign Exchange rate Adjustments | 13.08% | 578.79% | 600.00% | -258.36% | -20.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.88% | 107.03% | -3,453.09% | -4,051.83% | -402.56% |